|Description||JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.|
|Synonyms||JNJ-38877605; JNJ 38877605; JNJ38877605|
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
SGX523 is a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol/L an...
CEP-40783 is an orally-active, nanomolar potent and highly kinase-selective Type II inhibitor of the AXL and c-Met RTK with IC50 values of 7 nM and 12 nM, respe...
Tepotinib, also known as EMD 1214063 and MSC2156119, is an inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibito...
This active molecular is a c-MET and VEGFR inhibitor which is selective and specific in vitro. In vivo studies, TAS-115 suppressed the progression of MET-inacti...
golvatinib (also known as E7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial ...
Potent inhibitor of MET, VEGFR2, Ron and AXL (IC50 values are 0.4, 0.9, 3 and 11 nM, respectively). Also potently inhibits Tie-2, Flt-1, Flt-3, Flt-4, KIT, PDGF...
PF-04136309 is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral adminis...